Molecular Partners Ag (MOLN) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access MOLN Annual Income Statement →
The income statement data below highlights shifts in Molecular Partners Ag's operating performance over recent quarters.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2025)
Q4 2025
0 0 0 (Dec 31 2024)
Revenues
Revenue From Contracts With Customers0.00
Total Revenue0.00
Costs & Expenses
Gross Profit0.00
Selling, Administration, Marketing15.24
Research and Development Expense40.19
Other Operating Expense / -Income2.69
Total operating costs including COS58.12
Operating income / -loss-58.12
Net Interest Expense / -Income0.00
Other loss / -income3.53
Total costs & expenses61.65
Income & Taxes
Income / -loss before income taxes-61.65
Income taxes expenses / -benefit0.00
Income after income taxes-61.65
Income / -loss from continuing operations-61.65
Net income / -loss-61.65
Income / -loss to shareholder-61.65
EBIT-61.65
EBITD-61.65
EBITDA-61.65
Earnings Per Share
Basic EPS (excl. extra items)0.00
Basic Net EPS0.00
Basic shares outstanding (Mill. of Units)37.27
Diluted Net EPS0.00
Diluted average shares (Mill. of Units)37.27
4 historic quarters locked

Sign in to unlock the full Molecular Partners Ag income statement history.

About MOLN Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.